Open AccessSystemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
Author(s) -
Binet Quentin,
Hammer Frank D.,
Rocrelle Olivia,
Peeters André,
Scavée Christophe,
Hermans Cedric
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1446
Subject(s) - medicine , dabigatran , idarucizumab , thrombolysis , stroke (engine) , ischemic stroke , acute stroke , intensive care medicine , anesthesia , cardiology , tissue plasminogen activator , warfarin , myocardial infarction , atrial fibrillation , ischemia , mechanical engineering , engineering
Key Clinical Message Patients presenting with an acute ischemic stroke despite dabigatran therapy (last intake <24 h or unknown) should be evaluated for reversal by idarucizumab, making them eligible for safe and effective intravenous thrombolysis. It has been shown to be feasible, well‐tolerated, and easy to manage in an emergency room or stroke unit.